search
Back to results

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

Primary Purpose

Lax Skin

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Renuvion APR Device
Sponsored by
Apyx Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lax Skin focused on measuring Submental, Neck

Eligibility Criteria

35 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects 35-65 years of age (inclusive).
  2. Healthy as determined by the investigator examining the subject.
  3. Seeking improvement of the appearance of lax tissue in the neck and submental region.
  4. Females of childbearing potential who are sexually active must be willing to use an approved method of birth control during study participation.
  5. Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
  6. Willing to release rights for the use of study photos, including in potential publication.
  7. Understands and accepts the obligation not to have significant weight loss or weight gain (≥8 pounds) post the treatment, and for the duration of participation in the study.
  8. Willing to abstain from the use of blood thinners (including, but not limited to, Coumadin, NSAIDS, Ibuprofen, vitamin K, other) for 2 weeks (14 days) prior to the procedure.
  9. Willing to abstain from smoking, vaping, or the use of e-cigarettes for 1 year prior to and for the entire duration of participation in the study.
  10. Willing to abstain from the use of marijuana for 2 weeks prior to and for the duration of participation in the study.
  11. Able to read, understand, sign and date the informed consent document (English only).

Exclusion Criteria:

  1. Pregnant or lactating.
  2. Pregnancy within 12 months prior to screening.
  3. Use within 24 hours preceding surgery of ibuprofen, acetaminophen, any other analgesics, anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia).
  4. Allergy to tumescent anesthetic (lidocaine/epinephrine).
  5. Excessive subcutaneous fat in the treatment area (as determined by the treating investigator).
  6. Active systemic or local skin disease that may alter wound healing.
  7. Significant or uncontrolled medical condition that, in the opinion of the investigator, participation in the study may compromise the patient's health.
  8. Severe solar elastosis.
  9. History of autoimmune disease (excluding Hashimoto's thyroiditis).
  10. Known hypersensitivity or adverse reaction to anesthetics.
  11. Known susceptibility to keloid formation or hypertrophic scarring.
  12. Cancerous or pre-cancerous lesions in the area to be treated.
  13. History or current diagnosis of cancer of any type (excluding skin cancer).
  14. History of uncontrolled cardiovascular disease (i.e. myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other).
  15. History, or current bleeding disorders (i.e. hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants.
  16. Possesses a surgically implanted electronic device (i.e. pacemaker).
  17. History of AIDs/HIV.
  18. Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
  19. Chronic hypoxia or dependence on supplemental oxygen.
  20. Participation in any other investigational study within 30 days prior to consent.
  21. Any surgical or transdermal neck/submental aesthetic procedures or plans to undergo any other aesthetic procedure during study participation. Such procedures include, but are not limited to, submentoplasty, liposuction, ultrasound, cryolipolysis, radiofrequency, and laser.
  22. History of or current injury to the head and neck or any area of the body being treated as a part of this study.
  23. Presence of more than mild platysmal banding as per the Geister, et al Validated Assessment Scale for Platysmal Bands.
  24. Subject requiring removal of adipose tissue prior index procedure.
  25. A family member of the investigator or sponsor; an employee of the investigator or sponsor.
  26. Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.

Sites / Locations

  • Faces+ Plastic Surgery
  • West End Plastic Surgery
  • New Jersey Clinical Research Center
  • Luxurgery
  • H/K/B Cosmetic Surgery
  • Facial Plastic & Aesthetic Laser Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Study Phase I

Study Phase II

Arm Description

Subjects will be treated with the Renuvion APR device in the neck and submental region.

Subjects will be treated with the Renuvion APR device in the neck and submental region.

Outcomes

Primary Outcome Measures

Day 180 Number of Participants With Improvement Measured By Independent Photographic Review
Improvement in the appearance of lax tissue in the neck and submental region at 6 months as determined by qualitative 2D photography assessment by blinded Independent Photographic Reviewers. Three experienced, blinded photographic reviewers performed a qualitative analysis/review of the pre-treatment and post-treatment sets of images of each subject in a blinded and randomized order. Each blinded reviewer chose which image was the post-treatment image. Success was correct post-treatment image selection by at least 2 of the 3 reviewers. The percentage of subjects with a correct post-treatment image selection was calculated.
Subject Reported Pain - None to Moderate
The primary safety endpoint is the level of pain and discomfort after treatment as reported by the subject on an 11-point Numeric Rating Scale (NRS) through the 7-day follow-up visit where 0 is no pain and 10 is the most pain. Pain scores are classified as scores of 0 being no pain, 1 - 5 is minor pain, 6 - 7 is moderate pain, and 8 - 10 is severe pain. The primary safety objective is to demonstrate that the proportion of subjects with none-to- moderate pain exceeds the performance goal (PG). The performance goal is 55%.

Secondary Outcome Measures

Full Information

First Posted
October 29, 2019
Last Updated
July 11, 2022
Sponsor
Apyx Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT04146467
Brief Title
Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region
Official Title
A Prospective, Multi-Center, Evaluator-Blinded Study Evaluating the Safety and Effectiveness of the Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
November 26, 2019 (Actual)
Primary Completion Date
February 28, 2022 (Actual)
Study Completion Date
February 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Apyx Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, multi-center, multi-phase, evaluator-blinded study of subjects undergoing a procedure with the Renuvion APR Device to improve the appearance of lax tissue in the neck and submental region.
Detailed Description
This is a prospective, multi-center, multi-phase, evaluator-blinded study of subjects undergoing a procedure to improve the appearance of lax tissue in the neck and submental region. All study subjects will be treated with the Renuvion APR Device. Phase I (n=17) of this study will be conducted primarily to provide safety data, however, effectiveness data will also be collected at the above stated timepoints through 6 months post-procedure. Phase II (n=65) of this study is the expansion of the study to a pivotal study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lax Skin
Keywords
Submental, Neck

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
82 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study Phase I
Arm Type
Experimental
Arm Description
Subjects will be treated with the Renuvion APR device in the neck and submental region.
Arm Title
Study Phase II
Arm Type
Experimental
Arm Description
Subjects will be treated with the Renuvion APR device in the neck and submental region.
Intervention Type
Device
Intervention Name(s)
Renuvion APR Device
Intervention Description
The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
Primary Outcome Measure Information:
Title
Day 180 Number of Participants With Improvement Measured By Independent Photographic Review
Description
Improvement in the appearance of lax tissue in the neck and submental region at 6 months as determined by qualitative 2D photography assessment by blinded Independent Photographic Reviewers. Three experienced, blinded photographic reviewers performed a qualitative analysis/review of the pre-treatment and post-treatment sets of images of each subject in a blinded and randomized order. Each blinded reviewer chose which image was the post-treatment image. Success was correct post-treatment image selection by at least 2 of the 3 reviewers. The percentage of subjects with a correct post-treatment image selection was calculated.
Time Frame
180-Day
Title
Subject Reported Pain - None to Moderate
Description
The primary safety endpoint is the level of pain and discomfort after treatment as reported by the subject on an 11-point Numeric Rating Scale (NRS) through the 7-day follow-up visit where 0 is no pain and 10 is the most pain. Pain scores are classified as scores of 0 being no pain, 1 - 5 is minor pain, 6 - 7 is moderate pain, and 8 - 10 is severe pain. The primary safety objective is to demonstrate that the proportion of subjects with none-to- moderate pain exceeds the performance goal (PG). The performance goal is 55%.
Time Frame
Day 7
Other Pre-specified Outcome Measures:
Title
Day 90 Number of Participants With Improvement Measured By Independent Photographic Review
Description
Change in the appearance of lax tissue in the neck and submental region at 90-days as determined by qualitative 2D photography assessment by blinded Independent Photographic Reviewers. Three experienced, blinded photographic reviewers performed a qualitative analysis/review of the pre-treatment and post-treatment sets of images of each subject in a blinded and randomized order. Each blinded reviewer chose which image was the post-treatment image. Success was correct post-treatment image selection by at least 2 of the 3 reviewers. The percentage of subjects with a correct post-treatment image selection was calculated.
Time Frame
90-Day
Title
Subject Modified Global Aesthetic Improvement Scale (GAIS)
Description
Subject Modified GAIS: Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse
Time Frame
90-Day
Title
Subject Modified Global Aesthetic Improvement Scale (GAIS)
Description
Subject Modified GAIS: Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse
Time Frame
180-Day
Title
Investigator Modified Global Aesthetics Improvement Scale (GAIS)
Description
Investigator Modified GAIS:Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse
Time Frame
90-Day
Title
Investigator Modified Global Aesthetic Improvement Scale (GAIS)
Description
Investigator Modified GAIS: Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse
Time Frame
180-Day
Title
Day 180 Patient Satisfaction Questionnaire (PSQ) of Procedure
Description
At 180 days post procedure, the subject's satisfaction with the procedure was assessed using a Patient Satisfaction Questionnaire. Questions were YES or NO questions pertaining to satisfaction with study treatment, observations of improvement, and considerations for recommendation.
Time Frame
180-Day
Title
Quantitative Improvement in Overall Lift of the Neck and Submental Area
Description
Quantitative improvement in overall lift of the neck and submental area as determine by quantitative assessment based on 2D photography with Canfield Vectra system analysis. Fixed landmarks on the subject's face were used.
Time Frame
180-Day
Title
Quantitative Improvement in Submental Volume
Description
Quantitative improvement in submental volume at 180 days as determined by quantitative assessment based on 3D photography with Canfield Vectra system analysis.
Time Frame
180-Day
Title
Average Pain at Day 7 Reported by Subject
Description
Level of pain and discomfort after treatment as reported by the subject on a 11-point Numeric Rating Scale where 0 is "No Pain" and 10 is "Worst Possible Pain"
Time Frame
7-Day
Title
Median Pain Reported by Subject at Day 7
Description
Level of pain and discomfort after treatment as reported by the subject on a 11-point Numeric Rating Scale where 0 is "No Pain" and 10 is "Worst Possible Pain"
Time Frame
7-Day
Title
Average Pain Reported by Subject at Day 30
Description
Level of pain and discomfort after treatment as reported by the subject on a 11-point Numeric Rating Scale where 0 is "No Pain" and 10 is "Worst Possible Pain"
Time Frame
30-Day
Title
Median Pain Reported by Subject at Day 30
Description
Level of pain and discomfort after treatment as reported by the subject on a 11-point Numeric Rating Scale where 0 is "No Pain" and 10 is "Worst Possible Pain"
Time Frame
30-Day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects 35-65 years of age (inclusive). Healthy as determined by the investigator examining the subject. Seeking improvement of the appearance of lax tissue in the neck and submental region. Females of childbearing potential who are sexually active must be willing to use an approved method of birth control during study participation. Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits. Willing to release rights for the use of study photos, including in potential publication. Understands and accepts the obligation not to have significant weight loss or weight gain (≥8 pounds) post the treatment, and for the duration of participation in the study. Willing to abstain from the use of blood thinners (including, but not limited to, Coumadin, NSAIDS, Ibuprofen, vitamin K, other) for 2 weeks (14 days) prior to the procedure. Willing to abstain from smoking, vaping, or the use of e-cigarettes for 1 year prior to and for the entire duration of participation in the study. Willing to abstain from the use of marijuana for 2 weeks prior to and for the duration of participation in the study. Able to read, understand, sign and date the informed consent document (English only). Exclusion Criteria: Pregnant or lactating. Pregnancy within 12 months prior to screening. Use within 24 hours preceding surgery of ibuprofen, acetaminophen, any other analgesics, anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia). Allergy to tumescent anesthetic (lidocaine/epinephrine). Excessive subcutaneous fat in the treatment area (as determined by the treating investigator). Active systemic or local skin disease that may alter wound healing. Significant or uncontrolled medical condition that, in the opinion of the investigator, participation in the study may compromise the patient's health. Severe solar elastosis. History of autoimmune disease (excluding Hashimoto's thyroiditis). Known hypersensitivity or adverse reaction to anesthetics. Known susceptibility to keloid formation or hypertrophic scarring. Cancerous or pre-cancerous lesions in the area to be treated. History or current diagnosis of cancer of any type (excluding skin cancer). History of uncontrolled cardiovascular disease (i.e. myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other). History, or current bleeding disorders (i.e. hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants. Possesses a surgically implanted electronic device (i.e. pacemaker). History of AIDs/HIV. Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years. Chronic hypoxia or dependence on supplemental oxygen. Participation in any other investigational study within 30 days prior to consent. Any surgical or transdermal neck/submental aesthetic procedures or plans to undergo any other aesthetic procedure during study participation. Such procedures include, but are not limited to, submentoplasty, liposuction, ultrasound, cryolipolysis, radiofrequency, and laser. History of or current injury to the head and neck or any area of the body being treated as a part of this study. Presence of more than mild platysmal banding as per the Geister, et al Validated Assessment Scale for Platysmal Bands. Subject requiring removal of adipose tissue prior index procedure. A family member of the investigator or sponsor; an employee of the investigator or sponsor. Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul G Ruff IV, MD
Organizational Affiliation
West End Plastic Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faces+ Plastic Surgery
City
San Diego
State/Province
California
ZIP/Postal Code
92121
Country
United States
Facility Name
West End Plastic Surgery
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
New Jersey Clinical Research Center
City
Montclair
State/Province
New Jersey
ZIP/Postal Code
07042
Country
United States
Facility Name
Luxurgery
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
H/K/B Cosmetic Surgery
City
Huntersville
State/Province
North Carolina
ZIP/Postal Code
28078
Country
United States
Facility Name
Facial Plastic & Aesthetic Laser Center
City
Youngstown
State/Province
Ohio
ZIP/Postal Code
44512
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

We'll reach out to this number within 24 hrs